RA Capital Management L.P. Takes Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

RA Capital Management L.P. bought a new stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,181,818 shares of the company's stock, valued at approximately $23,705,000. RA Capital Management L.P. owned 4.66% of EyePoint Pharmaceuticals as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Geode Capital Management LLC lifted its stake in shares of EyePoint Pharmaceuticals by 16.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,199,056 shares of the company's stock valued at $9,583,000 after purchasing an additional 166,699 shares during the period. Barclays PLC lifted its stake in EyePoint Pharmaceuticals by 410.4% in the third quarter. Barclays PLC now owns 245,045 shares of the company's stock valued at $1,959,000 after buying an additional 197,033 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of EyePoint Pharmaceuticals by 1,171.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company's stock worth $2,970,000 after buying an additional 342,516 shares in the last quarter. Franklin Resources Inc. grew its position in shares of EyePoint Pharmaceuticals by 9.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company's stock worth $32,056,000 after buying an additional 362,399 shares during the period. Finally, abrdn plc bought a new stake in shares of EyePoint Pharmaceuticals in the 4th quarter valued at $1,719,000. Institutional investors own 99.41% of the company's stock.

EyePoint Pharmaceuticals Price Performance

Shares of EYPT stock traded up $0.17 during trading hours on Friday, reaching $7.30. The company had a trading volume of 690,968 shares, compared to its average volume of 879,558. The company has a market cap of $502.32 million, a price-to-earnings ratio of -3.65 and a beta of 1.39. EyePoint Pharmaceuticals, Inc. has a 12 month low of $3.91 and a 12 month high of $14.00. The business has a fifty day simple moving average of $6.00 and a 200-day simple moving average of $7.66.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The company had revenue of $11.60 million for the quarter, compared to the consensus estimate of $11.02 million. On average, equities research analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on EYPT shares. Citigroup initiated coverage on shares of EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating and a $33.00 price target for the company. Chardan Capital reaffirmed a "buy" rating and issued a $33.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. HC Wainwright reiterated a "buy" rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Finally, StockNews.com upgraded EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to data from MarketBeat, EyePoint Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $26.63.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.